Floatz logo

Autologous Anti-Cd19 Car-Expressing T-Lymphocytes Ic19/1563

Recurrent Transformed Chronic Lymphocytic Leukemia

Mayo ClinicCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Recurrent Transformed Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
PREDNISONE TABLETS
SWOG Cancer Research Network
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Anti-Cd19 Car-Expressing T-Lymphocytes Ic19/1563 is also rated in:

B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →